You are here: Industry Insights > Vitrakvi

News List

Pancreatic cancer market to reach $4.1 billion by 2029: GlobalData expresspharma
April 26, 2021
Growth in pancreatic cancer therapy market will be driven by the introduction of drugs with novel mechanisms of action, across several lines of therapies, which are poised to meet high unmet need in the US and 5EU.
FDA Approves Companion Diagnostic to Identify NTRK Fusions in Solid Tumors for Vitrakvi americanpharmaceuticalreview
November 02, 2020
The U.S. Food and Drug Administration (FDA) has approved the next-generation sequencing (NGS)-based FoundationOne CDx test (Foundation Medicine) as a companion diagnostic to identify fusions in neurotrophic receptor tyrosine kinase (NTRK) genes, NTRK1 ...
Bayer’s Vitrakvi shows long-term efficacy in TRK fusion-positive cancers pharmatimes
September 21, 2020
Bayer’s tumour agnostic therapy Vitrakvi has demonstrated sustained, long-term efficacy and safety in a number of tropomyosin receptor kinase (TRK) fusion-positive cancers, including lung and thyroid tumours.
NICE issues final guidance on NHS use of Bayer's Vitrakvi pharmatimes
May 28, 2020
The National Institute for Health and Care Excellence (NICE) has published final guidance recommending NHS use of Bayer's Vitrakvi (larotrectinib) for a variety of cancers.
NICE backs NHS use of Bayer's Vitrakvi via the CDF pharmatimes
April 26, 2020
Bayer's Vitrakvi (larotrectinib) will be available via the NHS in England and Wales to treat a variety of cancers.
NICE recommends Vitrakvi (larotrectinib) for use on Cancer Drugs Fund europeanpharmaceuticalreview
April 22, 2020
Larotrectinib has been given a positive opinion by NICE, following the submission of a revised price after it was previously rejected.
EMA recommends Vitrakvi for EU marketing authorisation europeanpharmaceuticalreview
July 30, 2019
The EMA has announced its approval for marketing authorisation in the EU for Vitrakvi (larotrectinib), used to treat solid tumours with a specific gene mutation.
Key European committee backs GW's Epidyolex, Bayer's Vitrakvi and more fiercepharma
July 28, 2019
In a busy meeting this week, experts with the European Medicines Agency's Committee for Medicinal Products for Human Use endorsed four new drugs, a Mylan generic, and numerous new indications for already-marketed meds.
Pipeline-hungry Bayer antes up on Vitrakvi, just as Roche’s would-be rival gets faster FDA review fiercepharma
February 24, 2019
Eager to pump up its pipeline—and hungry for present-day sales—Bayer has taken its chance to carve a piece out of Eli Lilly's $8 billion Loxo Oncology buyout.
Bayer to Obtain Rights to Vitrakvi and BAY 2731954 americanpharmaceuticalreview
February 18, 2019
Bayer has exercised its option, under a change-in-control clause in the collaboration agreement with Loxo Oncology, to obtain the exclusive licensing rights for the global development and commercialization...

Previous page 1 2 Next page